Intellia Therapeutics Q1 FY24: revenue $28.9M; diluted EPS −$1.12

Key figures from this report

These are the numbers Intellia Therapeutics reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Revenue$28.9MNo year-earlier figure tagged10-Q income statement, on EDGAR
2. Net income−$107.4MNo year-earlier figure tagged10-Q income statement, on EDGAR
3. Diluted EPS−$1.12No year-earlier figure tagged10-Q income statement, on EDGAR
4. Cash and cash equivalents$172.0MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
5. Cash from operations−$120.7MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables